deferoxamine has been researched along with Low Bone Density in 16 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The bone histology in patients with chronic renal failure and aluminum-related bone disease does not always show the excess accumulation of unmineralized osteoid (matrix) characteristic of osteomalacia." | 7.67 | Osteomalacia and aplastic bone disease in aluminum-related osteodystrophy. ( Andress, DL; Coburn, JW; Endres, DB; Maloney, NA; Sherrard, DJ, 1987) |
| "The bone histology in patients with chronic renal failure and aluminum-related bone disease does not always show the excess accumulation of unmineralized osteoid (matrix) characteristic of osteomalacia." | 3.67 | Osteomalacia and aplastic bone disease in aluminum-related osteodystrophy. ( Andress, DL; Coburn, JW; Endres, DB; Maloney, NA; Sherrard, DJ, 1987) |
| "Body disproportion and severe degree of osteopenia (BMD SDSBA -2." | 1.31 | Persistence of delayed adrenarche in boys with thalassemia. ( De Martinis, F; De Terlizzi, F; Di Maio, S; Esposito, G; Filosa, A, 2001) |
| "Nevertheless, osteopenia remains the main negative factor of thalassemia." | 1.29 | [The evolutionary effects of therapy on the skeletal lesions in beta-thalassemia]. ( Bariani, L; Castaldi, G; Orzincolo, C; Scutellari, PN, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (37.50) | 18.7374 |
| 1990's | 5 (31.25) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 1 (6.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hernández-Sánchez, A | 1 |
| Tejada-González, P | 1 |
| Arteta-Jiménez, M | 1 |
| Kashiwagi, T | 1 |
| Kurihara, S | 2 |
| Nakazawa, R | 2 |
| Vogiatzi, MG | 1 |
| Autio, KA | 1 |
| Mait, JE | 1 |
| Schneider, R | 1 |
| Lesser, M | 1 |
| Giardina, PJ | 1 |
| Orzincolo, C | 1 |
| Castaldi, G | 1 |
| Bariani, L | 1 |
| Scutellari, PN | 1 |
| Sulková, S | 1 |
| Filosa, A | 1 |
| Di Maio, S | 1 |
| Esposito, G | 1 |
| De Martinis, F | 1 |
| De Terlizzi, F | 1 |
| Marumo, F | 1 |
| Mazzaferro, S | 1 |
| Coen, G | 1 |
| Ballanti, P | 1 |
| Costantini, S | 1 |
| Bondatti, F | 1 |
| Giordano, R | 1 |
| Manni, M | 1 |
| Pasquali, M | 1 |
| Perruzza, I | 1 |
| Sardella, D | 1 |
| Klein, GL | 1 |
| Snodgrass, WR | 1 |
| Griffin, MP | 1 |
| Miller, NL | 1 |
| Alfrey, AC | 2 |
| Coburn, JW | 2 |
| Norris, KC | 1 |
| Sherrard, DJ | 2 |
| Bia, M | 1 |
| Llach, F | 1 |
| Slatopolsky, E | 1 |
| Andress, DL | 1 |
| Maloney, NA | 1 |
| Endres, DB | 1 |
| Williams, JW | 1 |
| Vera, SR | 1 |
| Peters, TG | 1 |
| Luther, RW | 1 |
| Bhattacharya, S | 1 |
| Spears, H | 1 |
| Graham, A | 1 |
| Pitcock, JA | 1 |
| Crawford, AJ | 1 |
| Palmieri, GM | 1 |
| Charhon, SA | 1 |
| Chavassieux, PM | 1 |
| Chapuy, MC | 1 |
| Traeger, J | 1 |
| Meunier, PJ | 1 |
4 reviews available for deferoxamine and Low Bone Density
| Article | Year |
|---|---|
Aluminium in parenteral nutrition: a systematic review.
Topics: Aluminum; Alzheimer Disease; Bone Diseases, Metabolic; Deferoxamine; Dyslipidemias; Humans; Iron; Ke | 2013 |
[Aluminum and iron deposition in dialysis patients].
Topics: Aluminum; Aluminum Hydroxide; Anemia; Bone Diseases, Metabolic; Contraindications; Deferoxamine; Dem | 2004 |
[The K/DOQI guidelines on diagnosis and treatment of aluminum bone disease in hemodialysis patients].
Topics: Aluminum; Biomarkers; Bone Diseases, Metabolic; Deferoxamine; Hemodiafiltration; Hemodialysis Soluti | 2004 |
Deferoxamine therapy of bone aluminum accumulation in renal dialysis patients.
Topics: Adolescent; Adult; Aluminum; Bone and Bones; Bone Diseases, Metabolic; Chelating Agents; Child; Chil | 1985 |
12 other studies available for deferoxamine and Low Bone Density
| Article | Year |
|---|---|
Low bone mineral density in adolescents with beta-thalassemia.
Topics: Adolescent; Adult; Anthropometry; beta-Thalassemia; Blood Transfusion; Bone Density; Bone Diseases, | 2005 |
[The evolutionary effects of therapy on the skeletal lesions in beta-thalassemia].
Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Bone and Bones; Bone Diseases, Metabolic; Ch | 1994 |
[Aluminum osteopathy--experience with therapy].
Topics: Aluminum; Bone Diseases, Metabolic; Deferoxamine; Female; Humans; Male; Middle Aged; Poisoning; Rena | 1993 |
Persistence of delayed adrenarche in boys with thalassemia.
Topics: Adolescent; Age Determination by Skeleton; Blood Transfusion; Body Height; Body Mass Index; Bone Den | 2001 |
[Dialysis bone disease associated with other factors].
Topics: Aluminum; Amyloidosis; Bone Diseases, Metabolic; Calcium Carbonate; Deferoxamine; Humans; Iron; Kidn | 1992 |
[Aluminum and iron deposition in dialysis patients].
Topics: Aluminum; Anemia; Bone Diseases, Metabolic; Deferoxamine; Erythropoietin; Humans; Iron; Kidney Failu | 1992 |
Deferoxamine test and PTH serum levels are useful not to recognize but to exclude aluminum-related bone disease.
Topics: Adult; Aluminum; Biopsy; Bone and Bones; Bone Diseases, Metabolic; Deferoxamine; Diagnostic Errors; | 1992 |
Hypocalcemia complicating deferoxamine therapy in an infant with parenteral nutrition-associated aluminum overload: evidence for a role of aluminum in the bone disease of infants.
Topics: Adult; Aluminum; Bone Diseases, Metabolic; Calcium; Deferoxamine; Female; Humans; Hypocalcemia; Infa | 1989 |
Toxic effects of aluminum in end-stage renal disease: discussion of a case.
Topics: Aluminum; Bone Diseases, Metabolic; Brain Diseases; Deferoxamine; Female; Hemodialysis, Home; Humans | 1988 |
Osteomalacia and aplastic bone disease in aluminum-related osteodystrophy.
Topics: Adult; Aluminum; Bone Diseases, Metabolic; Deferoxamine; Female; Humans; Male; Middle Aged; Osteomal | 1987 |
Biliary excretion of aluminum in aluminum osteodystrophy with liver disease.
Topics: Adult; Aluminum; Aluminum Hydroxide; Bile; Bone and Bones; Bone Diseases, Metabolic; Chronic Disease | 1986 |
High bone turnover associated with an aluminum-induced impairment of bone mineralization.
Topics: Aluminum; Biopsy; Bone and Bones; Bone Diseases, Metabolic; Deferoxamine; Humans; Hyperparathyroidis | 1986 |